133 related articles for article (PubMed ID: 35468992)
21. The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection.
Carlos AJ; Ha DP; Yeh DW; Van Krieken R; Tseng CC; Zhang P; Gill P; Machida K; Lee AS
J Biol Chem; 2021; 296():100759. PubMed ID: 33965375
[TBL] [Abstract][Full Text] [Related]
22. Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells.
Zhou L; Huntington K; Zhang S; Carlsen L; So EY; Parker C; Sahin I; Safran H; Kamle S; Lee CM; Lee CG; Elias JA; Campbell KS; Naik MT; Atwood WJ; Youssef E; Pachter JA; Navaraj A; Seyhan AA; Liang O; El-Deiry WS
bioRxiv; 2020 Sep; ():. PubMed ID: 32793908
[TBL] [Abstract][Full Text] [Related]
23. Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces.
Lapaillerie D; Charlier C; Guyonnet-Dupérat V; Murigneux E; Fernandes HS; Martins FG; Magalhães RP; Vieira TF; Richetta C; Subra F; Lebourgeois S; Charpentier C; Descamps D; Visseaux B; Weigel P; Favereaux A; Beauvineau C; Buron F; Teulade-Fichou MP; Routier S; Gallois-Montbrun S; Meertens L; Delelis O; Sousa SF; Parissi V
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0008322. PubMed ID: 35861550
[TBL] [Abstract][Full Text] [Related]
24. Low dose radiation therapy attenuates ACE2 depression and inflammatory cytokines induction by COVID-19 viral spike protein in human bronchial epithelial cells.
Wen K; Bai C; Zhao H; Zhou P; Gao S; Guan H; Song M
Int J Radiat Biol; 2022; 98(10):1532-1541. PubMed ID: 35319335
[No Abstract] [Full Text] [Related]
25. Proteomic identification of the oncoprotein STAT3 as a target of a novel Skp1 inhibitor.
Cheng X; Liu YQ; Wang GZ; Yang LN; Lu YZ; Li XC; Zhou B; Qu LW; Wang XL; Cheng YX; Liu J; Tao SC; Zhou GB
Oncotarget; 2017 Jan; 8(2):2681-2693. PubMed ID: 27835873
[TBL] [Abstract][Full Text] [Related]
26. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
[TBL] [Abstract][Full Text] [Related]
27. SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice.
Winkler ES; Chen RE; Alam F; Yildiz S; Case JB; Uccellini MB; Holtzman MJ; Garcia-Sastre A; Schotsaert M; Diamond MS
J Virol; 2022 Jan; 96(1):e0151121. PubMed ID: 34668780
[TBL] [Abstract][Full Text] [Related]
28. Obesogenic and Ketogenic Diets Distinctly Regulate the SARS-CoV-2 Entry Proteins ACE2 and TMPRSS2 and the Renin-Angiotensin System in Rat Lung and Heart Tissues.
Da Eira D; Jani S; Ceddia RB
Nutrients; 2021 Sep; 13(10):. PubMed ID: 34684358
[TBL] [Abstract][Full Text] [Related]
29. Expressions and significances of the angiotensin-converting enzyme 2 gene, the receptor of SARS-CoV-2 for COVID-19.
Fu J; Zhou B; Zhang L; Balaji KS; Wei C; Liu X; Chen H; Peng J; Fu J
Mol Biol Rep; 2020 Jun; 47(6):4383-4392. PubMed ID: 32410141
[TBL] [Abstract][Full Text] [Related]
30. An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension.
Fuchs E; Rudnik-Jansen I; Dinesen A; Selnihhin D; Mandrup OA; Thiam K; Kjems J; Pedersen FS; Howard KA
Acta Biomater; 2022 Nov; 153():411-418. PubMed ID: 36162760
[TBL] [Abstract][Full Text] [Related]
31. Asthma Associated Cytokines Regulate the Expression of SARS-CoV-2 Receptor ACE2 in the Lung Tissue of Asthmatic Patients.
Saheb Sharif-Askari F; Goel S; Saheb Sharif-Askari N; Hafezi S; Al Heialy S; Hachim MY; Hachim IY; Mahboub B; Salameh L; Abdelrazig M; Elzain EI; Al-Muhsen S; Al-Hajjaj MS; Ratemi E; Hamid Q; Halwani R
Front Immunol; 2021; 12():796094. PubMed ID: 35111161
[TBL] [Abstract][Full Text] [Related]
32. Pathophysiological conditions induced by SARS-CoV-2 infection reduce ACE2 expression in the lung.
Miura Y; Ohkubo H; Nakano A; Bourke JE; Kanazawa S
Front Immunol; 2022; 13():1028613. PubMed ID: 36405683
[TBL] [Abstract][Full Text] [Related]
33. SARS-CoV-2 spike protein enhances MAP4K3/GLK-induced ACE2 stability in COVID-19.
Chuang HC; Hsueh CH; Hsu PM; Huang RH; Tsai CY; Chung NH; Chow YH; Tan TH
EMBO Mol Med; 2022 Sep; 14(9):e15904. PubMed ID: 35894122
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS-CoV-2 infectivity.
Saiz ML; DeDiego ML; López-García D; Corte-Iglesias V; Baragaño Raneros A; Astola I; Asensi V; López-Larrea C; Suarez-Alvarez B
Clin Epigenetics; 2021 Oct; 13(1):187. PubMed ID: 34635175
[TBL] [Abstract][Full Text] [Related]
35. Evaluating angiotensin-converting enzyme 2-mediated SARS-CoV-2 entry across species.
Zhang HL; Li YM; Sun J; Zhang YY; Wang TY; Sun MX; Wang MH; Yang YL; Hu XL; Tang YD; Zhao J; Cai X
J Biol Chem; 2021; 296():100435. PubMed ID: 33610551
[TBL] [Abstract][Full Text] [Related]
36. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
37. The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19.
Ahmad I; Pawara R; Surana S; Patel H
Top Curr Chem (Cham); 2021 Oct; 379(6):40. PubMed ID: 34623536
[TBL] [Abstract][Full Text] [Related]
38. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
39. Tinocordiside from
Balkrishna A; Pokhrel S; Varshney A
Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
[TBL] [Abstract][Full Text] [Related]
40. Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart.
Liu H; Gai S; Wang X; Zeng J; Sun C; Zhao Y; Zheng Z
Cardiovasc Res; 2020 Aug; 116(10):1733-1741. PubMed ID: 32638018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
